Sanofi, Alnylam Complete Research Phase of Rare Disease Alliance
April 08 2019 - 01:46AM
Dow Jones News
By Nathan Allen
Sanofi SA (SAN.FR) said Monday that it has concluded the
research-and-option phase of its rare-disease alliance with Alnylam
Pharmaceuticals Inc. (ALNY)
Through the alliance, which was set up in 2014, the companies
developed a treatment for patients with ATTR amyloidosis and are
testing a molecule to treat hemophilia, Sanofi said.
In the new phase of the alliance Alnylam will proceed with
another early-stage therapy for an undisclosed rare disease, taking
it through to initial trials.
Sanofi said it will then be responsible for any further
development of the therapy, paying royalties to Alnylam from global
sales.
The two companies have amended their equity agreement, with
France's Sanofi obtaining a release from its lock-up of trading in
Alnylam's shares.
Write to Nathan Allen at nathan.allen@dowjones.com
(END) Dow Jones Newswires
April 08, 2019 01:31 ET (05:31 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2023 to Mar 2024